Anticoagulation versus placebo for heart failure in sinus rhythm-Reference-Cited by-同舟云学术

Anticoagulation versus placebo for heart failure in sinus rhythm

Published:2021-05-18 Issue:5 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Shantsila Eduard¹,Kozieł Monika²³,Lip Gregory YH⁴

Affiliation:

1. University of Birmingham, Institute of Cardiovascular Sciences; City Hospital, Sandwell and West Birmingham Hospitals NHS Trust; Birmingham UK

2. Liverpool Centre for Cardiovascular Science; University of Liverpool and Liverpool Heart & Chest Hospital; Liverpool UK

3. 1st Department of Cardiology and Angiology; Silesian Centre for Heart Diseases; Zabrze Poland

4. Institute of Ageing and Chronic Disease; University of Liverpool; Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference52 articles.

1. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial;Mehra;European Heart Journal

2. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease;Zannad;New England Journal of Medicine,2018

3. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study;Cokkinos;European Journal of Heart Failure,2006

4. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure;Cleland;American Heart Journal,2004

5. The effects of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure;Anderson;American Heart Journal,1950

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of Left Ventricular Thrombus Formation;Advances in Clinical Medicine;2024

2. Interaction of heart failure and stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis;European Journal of Heart Failure;2023-12

3. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society;Kardiologia Polska;2023-05-29

4. Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association;Circulation;2022-10-11

5. Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation;Scientific Reports;2022-09-22